No major health authority has concluded that COVID-19 vaccines cause colon cancer, and the direct evidence against such a link is considerably stronger than the evidence for it. That said, several large observational studies published between 2024 and 2025 have flagged statistical associations between vaccination and subsequent cancer diagnoses, including colorectal cancer, that researchers are still working to explain. The question is genuine enough to deserve a careful look at what the data actually show, what the known confounders are, and why some of those signals almost certainly reflect the chaos of the pandemic rather than a biological effect of the vaccines themselves.
What the Observational Studies Found
Two large cohort studies have drawn the most attention. A population-based study in South Korea, covering millions of individuals, found that the risk of a colorectal cancer diagnosis was roughly 28% higher in vaccinated people compared with unvaccinated controls at one year after vaccination. Both mRNA and adenoviral-vector (“cDNA”) vaccines were linked to the colorectal signal. The same study found elevated risks for several other cancer types as well, including thyroid, gastric, lung, breast, and prostate cancers.1PubMed Central. 1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea Separately, a 30-month cohort study in an Italian province reported a similar pattern: at least one vaccine dose was associated with about a 34% higher risk of hospitalization for colorectal cancer.2EXCLI Journal. COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province
These are not trivial findings, and they have understandably gotten people’s attention. But a hazard ratio of 1.28 or 1.34 in an observational study sits in a range where confounding factors can easily manufacture a false signal. These studies measured associations, not causes, and several specific confounders make interpretation especially tricky for cancer outcomes during the pandemic years.
Why an Association Does Not Mean Causation Here
The single biggest confounder is what epidemiologists call “healthy vaccinee bias” working in reverse. During the pandemic, people who got vaccinated were, on average, more engaged with the healthcare system. They were more likely to see doctors, get routine screenings, and follow up on symptoms. People who remained unvaccinated were, on average, less connected to medical care. That difference alone can create a statistical gap: vaccinated people get diagnosed with cancers that were already growing because they were the ones showing up for colonoscopies and checkups. Unvaccinated people with the same cancers may simply not have been diagnosed yet during the study period.
This detection bias is especially relevant for colorectal cancer, which develops slowly over years. Colon polyps typically take a decade or more to progress to invasive cancer. A cancer diagnosed within a year of vaccination almost certainly began growing long before the vaccine was administered. For the vaccine to have “caused” those cancers, it would need to have initiated and accelerated the entire multi-year process of malignant transformation in under twelve months, something that does not match what we know about how solid tumors develop.
There is also the issue of pandemic-era screening disruptions working their way through the data, which deserves its own discussion.
The Pandemic Screening Gap
When hospitals shut down elective procedures in 2020, colorectal cancer screening essentially halted for months. Colonoscopies were postponed, stool-based screening kits went unused, and patients with concerning symptoms delayed seeking care. The consequences were predictable and well documented. A modeling study estimated that screening delays beyond 12 months would lead to a significant increase in advanced-stage colorectal cancer diagnoses and roughly a 12% increase in total cancer deaths compared with a baseline of timely screening.3PubMed Central. Impact of SARS-CoV-2 Pandemic on Colorectal Cancer Screening Delay: Effect on Stage Shift and Increased Mortality A separate study examining actual diagnosis patterns found that advanced-stage disease (stage IV) was more frequent during the pandemic period than before it.4PubMed Central. Impact of the COVID-19 pandemic in colorectal cancer diagnosis and presentation
When screenings resumed, they resumed largely among vaccinated populations, because vaccination requirements or strong recommendations were often tied to healthcare access. The catch-up wave of diagnoses that followed would naturally cluster among vaccinated individuals, not because the vaccine gave them cancer, but because they were the ones getting screened again. This creates a statistical artifact that is extremely difficult to fully adjust for in observational data, and both the Korean and Italian studies acknowledge they cannot rule it out.
Could SARS-CoV-2 Itself Be Involved?
A question that gets much less social-media attention but more scientific interest is whether the virus, not the vaccine, might contribute to gastrointestinal cancers. SARS-CoV-2 enters cells through the ACE2 receptor, which is heavily expressed in the lining of the gut. A growing body of research suggests that the virus may promote gastrointestinal malignancies through sustained chronic inflammation, disruption of normal cellular processes, and possible viral integration into host DNA.5PubMed Central. Exploring the oncogenic potential of SARS-CoV-2 in the gastrointestinal tract These are the same broad mechanisms that certain other viruses use to promote cancer, though the evidence for SARS-CoV-2 doing so is still preliminary.
This matters because in the observational studies cited above, the vaccinated group was not compared against people who had never been exposed to the virus. They were compared against unvaccinated people, many of whom had also been infected with SARS-CoV-2. If the virus itself carries some oncogenic risk, the comparison is muddied further. And a review of case reports across both vaccinated and infected individuals found recurring themes: unusually rapid progression or reactivation of previously controlled cancers, atypical patterns of disease, and proposed immune-related links between either the infection or the vaccination and shifts in tumor behavior.6PubMed Central. COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms The fact that both infection and vaccination appear in these reports suggests the immune disruption of the pandemic as a whole, not one specific exposure, may be what researchers need to untangle.
The Biological Mechanism Hypothesis
For the vaccine-causes-cancer claim to hold up, there needs to be a plausible biological mechanism. One hypothesis paper has proposed that in certain susceptible individuals, the modified mRNA used in vaccines might not be cleared from cells efficiently. If it persists, the theory goes, it could activate mobile genetic elements called transposable elements, potentially leading to DNA damage, disruption of tumor-suppressor genes, and chronic inflammation that could promote cancer over time.7PubMed Central. Potential health risks of mRNA-based vaccine therapy: A hypothesis
This is explicitly a hypothesis, not an experimental finding. The authors are describing what could theoretically happen under a specific chain of unlikely events. No study has demonstrated that vaccine mRNA actually triggers insertional mutagenesis in human cells. The modified mRNA used in vaccines is designed to be translated into protein and then degraded, and existing evidence suggests it is cleared within days. That does not mean the hypothesis is worthless — hypotheses are how science identifies what to test next — but it is a long way from being evidence that the vaccines cause colon cancer or any other cancer. Treating a speculative mechanism paper as if it were an epidemiological finding is a common mistake in public discussions of this topic.
What Happens When Cancer Patients Get Vaccinated
If COVID-19 vaccines promoted colon cancer, you would expect to see the signal most clearly in people who already had the disease. Vaccinated colorectal cancer patients should show faster progression, more recurrences, or worse outcomes than unvaccinated ones. The available evidence does not support this.
A study directly comparing disease progression in colorectal cancer patients who received the vaccine against those who did not found no significant difference in short-term recurrence or progression over a median follow-up of eight months.8Journal of Clinical Oncology. The safety assessment of COVID-19 vaccine injection in patients with colorectal cancer Multiple studies of the Pfizer-BioNTech vaccine in cancer patients undergoing active treatment found it was well tolerated, with severe side effects occurring in about 1% of cases and no grade 3 or 4 side effects reported in some cohorts.9PubMed Central. Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study10PubMed Central. COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy The main clinical concern with vaccinating cancer patients was not safety but effectiveness: patients on chemotherapy produced lower antibody levels than healthy people, meaning the vaccine worked less well, not that it was more dangerous.11JNCI: Journal of the National Cancer Institute. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients
Current oncology guidelines continue to recommend that cancer patients be prioritized for COVID-19 vaccination because of their weakened immune systems. The guidelines advise timing the vaccine before chemotherapy starts when possible, or between treatment cycles, but emphasize that treatment should not be delayed for the sake of vaccination.12PubMed Central. COVID-19 Vaccination in Cancer Patients: A Review Article
Active Surveillance Has Not Flagged a Cancer Signal
In the United States, vaccine safety monitoring began the week the first COVID-19 shots were administered in December 2020. The Vaccine Safety Datalink, a long-running collaboration between several large health systems and the CDC, conducted weekly rapid-cycle analyses specifically designed to catch unexpected safety signals.13JAMA. Surveillance for Adverse Events After COVID-19 mRNA Vaccination These systems are not perfect, and they are better at catching acute events like myocarditis than slow-developing conditions like cancer. But after more than four years of surveillance across hundreds of millions of doses, no formal safety signal for any cancer type has been triggered by these monitoring systems. That does not prove the absence of a tiny long-term risk, but it puts a ceiling on how large any such risk could plausibly be.
One Unusual Finding About Microsatellite Status
One small study did report an intriguing finding that has not been replicated. Among patients with newly diagnosed non-metastatic colon cancer, those who had received the Pfizer-BioNTech vaccine were more likely to have tumors with a specific molecular profile called mismatch-repair deficiency, or dMMR. The association was statistically significant, with vaccinated patients showing roughly six times the odds of having dMMR tumors compared with unvaccinated patients.14PubMed Central. Types and Rates of COVID-19 Vaccination in Patients With Newly Diagnosed Microsatellite Stable and Instable Non-Metastatic Colon Cancer
This is the kind of finding that sounds alarming out of context but needs careful interpretation. The study was small, and the result could easily be a statistical artifact of sample size. Mismatch-repair deficiency is actually associated with better prognosis in early-stage colon cancer and makes tumors more responsive to immunotherapy. One possible explanation that does not involve the vaccine causing anything is that the immune stimulation from vaccination may have made dMMR tumors (which are already more visible to the immune system) more clinically apparent, leading to earlier detection. Another is simple chance in a small sample. The authors themselves framed it as a preliminary observation, not a causal claim, and no larger study has confirmed the pattern.
The Gut Microbiome Question
Because the gut microbiome plays a role in colorectal cancer risk, some people have wondered whether COVID-19 vaccination might alter gut bacteria in ways that promote tumor growth. A study that tracked gut microbiome composition in both healthy and immunocompromised individuals before and after vaccination found no evidence that the vaccine promoted changes in the abundance of microbes associated with immune-related diseases.15PubMed Central. Stability of gut microbiome after COVID-19 vaccination in healthy and immuno-compromised individuals The gut microbiome remained stable through the vaccination series, which is consistent with what you would expect from an intramuscular injection that does not directly interact with the digestive tract.
Early-Onset Colorectal Cancer Was Rising Before COVID
Part of what fuels concern about vaccines and colon cancer is the real and alarming rise in colorectal cancer among younger adults. But this trend predates both the pandemic and the vaccines by decades. The incidence of colorectal cancer in people under 50 has been climbing steadily across high-income countries for years, driven by factors researchers are still working to fully identify but that likely include changes in diet, obesity rates, sedentary behavior, and environmental exposures.16PubMed Central. Rising incidence of early-onset colorectal cancer – a call to action When people notice more young adults being diagnosed with colon cancer and look for a recent cause, the COVID vaccine is a tempting candidate. But the curve was already heading upward well before 2020, and attributing a decades-long trend to a vaccine introduced in late 2020 does not fit the timeline.
mRNA Technology Is Being Developed to Treat Colon Cancer
In an ironic twist, the same mRNA platform used in COVID-19 vaccines is now one of the most active areas of colorectal cancer treatment research. Scientists are developing personalized mRNA vaccines that train a patient’s immune system to recognize and attack their specific tumor. The approach is being called a potential new direction in cancer treatment, with researchers designing multi-epitope vaccines tailored to tumor-specific markers found in colorectal cancers.17PubMed. The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy18PubMed Central. A novel multi-epitope mRNA vaccine against colorectal cancer: in silico design and immune efficacy profiling Early clinical work suggests these therapeutic vaccines have a manageable safety profile and show initial signs of antitumor activity.19PubMed Central. The evolution of vaccine strategies for colorectal cancer: from conventional approaches to the mRNA era
Meanwhile, research into repurposing the COVID-19 vaccines themselves for cancer treatment has shown that the innate immune response triggered by mRNA vaccines can reshape the environment around tumors in ways that make them more vulnerable to immunotherapy. In laboratory and early clinical settings, this immune boost helped checkpoint-inhibitor drugs work against cancer types that normally resist them.20Journal for ImmunoTherotherapy of Cancer. Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directions None of this proves the COVID vaccine prevents colon cancer, but it does illustrate that the immune activation caused by these vaccines can work against tumors rather than promote them, which is relevant context when weighing the biological plausibility of the opposing claim.